A RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY GEFITINIB AS MAINTENANCE WITH GEFITINIB MONOTHERAPY IN EAST ASIAN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSQNSCLC)

被引：0
|
作者：
Yang, James C. [1 ]
Park, Keunchil [2 ]
Mok, Tony Shu Kam [3 ]
Kang, Jin Hyoung [4 ]
Srimuninnimit, Vichien [5 ]
Lin, Chia-Chi [1 ]
Kim, Dong-Wan [6 ]
Tsai, Chun-Ming [7 ]
Barraclough, Helen [8 ]
Altug, Sedat [9 ]
Orlando, Mauro [10 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Samsung Med Ctr, Seoul, South Korea
[3] Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[4] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[5] Mahidol Univ, Div Med Oncol, Bangkok 10700, Thailand
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Taipei Vet Gen Hosp, Taipei, Taiwan
[8] Eli Lilly Australia, West Ryde, NSW, Australia
[9] Eli Lilly Instanbul, Istanbul, Turkey
[10] Eli Lilly Interamer Inc, Buenos Aires, DF, Argentina
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; East-Asian patients; non-small cell lung cancer; pemetrexed;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO06.04
引用
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [21] A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non-small cell lung cancer in East Asian patients.
    Yang, C.
    Yu, C.
    Chen, K.
    Lin, Z.
    Kuo, S.
    Hwang, T.
    Cheng, A.
    Yang, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 405S - 405S
  • [22] GEFITINIB AS FIRST-LINE THERAPY FOR ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS IN SOUTHERN TAIWAN
    Yang, Cheng-Ta
    Hung, Jen-Yu
    Lai, Chun-Liang
    Hung, Hsin-Chia
    Lai, Yung-Fa
    Lin, Meng-Chih
    Shieh, Jiunn-Min
    Huang, Ming-Shyang
    [J]. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2010, 26 (01): : 1 - 7
  • [23] Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
    Gray, Jhanelle Elaine
    Owonikoko, Taofeek Kunle
    Kato, Terufumi
    Zorrilla, Andres Felipe Cardona
    Wagman, Joanne
    Chen, Xinqun
    Zhao, Bin
    Schulz, Christian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [25] A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer
    Rodrigues-Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae Ho
    Wang, Jie
    Ganju, Vinod
    Martinez-Barrera, Luis
    Barraclough, Helen
    van Kooten, Maximiliano
    Orlando, Mauro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : 1907 - 1914
  • [26] EFFICACY AND SAFETY OF CISPLATIN/PEMETREXED AS FIRST-LINE TREATMENT FOR JAPANESE PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Yamaguchi, Teppei
    Nakanishi, Toru
    Hayashi, Masamichi
    Isogai, Sumito
    Hoshino, Tami
    Mieno, Yuki
    Uozu, Sakurako
    Morishita, Mariko
    Okamura, Takuya
    Takeyama, Tomoko
    Minezawa, Tomoyuki
    Morikawa, Sayako
    Niwa, Yoshikazu
    Okazawa, Mitsushi
    Imaizumi, Kazuyoshi
    [J]. RESPIROLOGY, 2013, 18 : 83 - 83
  • [27] Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
    Uchibori, Ken
    Satouchi, Miyako
    Sueoka-Aragane, Naoko
    Urata, Yoshiko
    Sato, Akemi
    Imamura, Fumio
    Inoue, Takako
    Tachihara, Motoko
    Kobayashi, Kazuyuki
    Katakami, Nobuyuki
    Kokan, Chiyuki
    Hirashima, Tomonori
    Iwanaga, Kentaro
    Mori, Masahide
    Aoe, Keisuke
    Morita, Satoshi
    Negoro, Shunichi
    [J]. LUNG CANCER, 2018, 124 : 65 - 70
  • [28] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Motohiro Tamiya
    Akihiro Tamiya
    Hiroyasu Kaneda
    Kazuhiko Nakagawa
    Kiyotaka Yoh
    Koichi Goto
    Hiroaki Okamoto
    Tsuneo Shimokawa
    Tetsuya Abe
    Hiroshi Tanaka
    Haruko Daga
    Koji Takeda
    Tomonori Hirashima
    Shinji Atagi
    [J]. Medical Oncology, 2016, 33
  • [29] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Yoh, Kiyotaka
    Goto, Koichi
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Abe, Tetsuya
    Tanaka, Hiroshi
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    [J]. MEDICAL ONCOLOGY, 2016, 33 (01) : 1 - 7
  • [30] Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer
    Pereira J.R.
    Cheng R.
    Orlando M.
    Kim J.-H.
    Barraclough H.
    [J]. Drugs in R&D, 2013, 13 (4) : 289 - 296
12345